Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 8, Number 8—August 2002

Research

Outbreak of Serogroup W135 Meningococcal Disease after the Hajj Pilgrimage, Europe, 2000

Jean-François Aguilera*Comments to Author , Anne Perrocheau†, Christine Meffre‡, Susan Hahné§, and the W135 Working Group1
Author affiliations: *Communicable Disease Surveillance Centre, London, United Kingdom; †Institut de Veille Sanitaire, St. Maurice, France; ‡Rijksinstituut voor Volksgezondheid en Milieu (RIVM), European Programme for Intervention Epidemiology Training, Bilthoven, the Netherlands; §Communicable Disease Surveillance Centre, Cardiff, Wales, United Kingdom

Main Article

Table 1

Cases of W135 meningococcal disease reported from nine European countries following Hajj, 2000

UK (no., % ; n=42) France (no., % ; n=24) All other countries (no., % ; n=24) a Total (no., % ; n=90)
Sex ratio (M/F) 0.6 0.7 1.7 0.9
Age distribution
<1 year 6 (14) 3 (13) 5 (21) 14 (16)
1–4 14 (33) 7 (29) 14 (58) 35 (39)
5–9 6 (14) 2 (8) 0 8 (9)
10–19 0 2 (8) 1 (4) 3 (3)
20–49 7 (17) 3 (13) 1 (4) 10 (11)
50–65 5 (12) 4 (17) 0 10 (11)
>65 4 (10) 3 (13) 1 (4) 8 (9)
Unknown 0 0 2 2
No. of deaths
<1 year 0 0 0 0
1–4 1 1 2 4
5–9 1 0 0 1
10–19 0 0 0 0
20–49 3 1 0 4
50-64 1 1 0 2
>65 2 1 0 3
CFR (overall) 19.0% 16.7% 8.3% 15.6%

aThe Netherlands, Germany, Finland, Sweden, Belgium, Norway, and Switzerland.
CFR, case-fatality rate.
UK, United Kingdom.

Main Article

1F. Carion and O. Ronveaux, Institut de Santé Publique, Brussels, Belgium; P. Nuorti, H. Kayhty, and N. Nguyen Tran Minh, Kansanterveyslaitos Folkhälsoinstitutet, National Public Health Institute, Helsinki, Finland; T. Breuer, U. Menzel, and V. Bremer, Robert Koch Institute, Berlin, Germany; J. Kool, Rijksinstituut voor Volksgezondheid en Milieu, Bilthoven, the Netherlands; L. Spanjaard, Netherlands Reference Laboratory for Bacterial Meningitis, Amsterdam, the Netherlands; M. Arneborn and H. Götz, Smittskyddinstitutet, Stockholm, Sweden; P.Olcen, National Meningitidis Reference Laboratory, Örebro, Sweden; M. Ramsay, N. Noah, and E. Kaczmarski, Public Health Laboratory Service (PHLS), London, United Kingdom; J. Stuart, PHLS, Gloucester, United Kingdom; D. Levy-Bruhl, M.D. Matsika-Claquin, and J.C. Desenclos, Institut National de Veille Sanitaire, St-Maurice, France; M.K. Taha, Institut Pasteur, Paris, France; B. Iversen and D. Caugant, Folkehelsa, Oslo, Norway.

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO